- In April 2024, Hologic, Inc., a global leader in women’s health, announced the U.S. FDA clearance of its new Brevera Breast Biopsy System with CorLumina imaging technology. This all-in-one system streamlines the biopsy process by combining tissue acquisition, real-time imaging, and verification in a single step, reducing procedure time and enhancing patient comfort. The development underscores Hologic’s ongoing commitment to innovation in image-guided breast biopsy solutions and improving workflow efficiency in clinical settings.
- In March 2024, BD (Becton, Dickinson and Company) launched the BD UltraCore Biopsy Device in North America, targeting enhanced precision for core needle biopsy procedures. The device features a dual-spring system that improves tissue capture while minimizing patient trauma. The launch aligns with the rising demand for minimally invasive biopsy tools and supports BD’s expansion in the high-growth breast diagnostics segment.
- In February 2024, Stryker Corporation announced a strategic partnership with multiple ambulatory surgical centers (ASCs) across the U.S. to deploy its advanced breast biopsy navigation software, designed to assist surgeons in more accurately locating and sampling suspicious lesions. This partnership reflects the growing role of software-enabled biopsy guidance in improving diagnostic accuracy and supporting outpatient breast cancer diagnostics.
- In January 2024, Siemens Healthineers introduced an upgraded version of its MAMMOMAT Revelation system in the Canadian market, integrated with 3D-guided breast biopsy capability. The system provides automated breast density assessment and biopsy planning tools, enabling radiologists to perform complex biopsies with increased confidence and efficiency. This expansion strengthens Siemens’ footprint in the Canadian diagnostic imaging and biopsy equipment sector.
- In December 2023, Devicor Medical Products (a Leica Biosystems company) received Health Canada approval for its MammoMARK Biopsy Site Marker, an advanced tissue marking solution used post-biopsy for site localization in follow-up treatments. The launch is expected to improve accuracy in surgical planning and reinforces Devicor’s leadership in post-biopsy care and tissue marking technologies in the North American region.
